Page last updated: 2024-11-13

desferrithiocin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

desferrithiocin: a siderophore; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID101609363
MeSH IDM0143535

Synonyms (2)

Synonym
desferrithiocin
Q27291146

Research Excerpts

Overview

Desferrithiocin (DFT) is an orally effective Fe chelator, with a similar high affinity and selectivity for Fe to desferrioxamine (DFO) DFO has been shown clinically to possess antineoplastic activity.

ExcerptReferenceRelevance
"Desferrithiocin (DFT, 1) is a very efficient iron chelator when given orally. "( Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.
Bergeron, RJ; Bharti, N; McManis, JS; Wiegand, J, 2012
)
2.13
"Desferrithiocin (DFT) is an orally effective Fe chelator, with a similar high affinity and selectivity for Fe to desferrioxamine (DFO), which has been shown clinically to possess antineoplastic activity. "( Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.
Baker, E; Chua, AC; Kicic, A, 2002
)
3.2
"Desferrithiocin is a new, potent, orally available iron chelator. "( The effect of desferrithiocin, an oral iron chelator, on T-cell function.
Bierer, BE; Nathan, DG, 1990
)
2.08

Effects

ExcerptReferenceRelevance
"3H-Desferrithiocin (DFT) has been synthesized from desmethyl desferrithiocin. "( Desferrithiocin and desferrioxamine B. Cellular pharmacology and storage iron mobilization.
Baquet, A; Crichton, RR; Florence, A; Jin, Y; Schneider, YJ, 1989
)
2.34

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic behavior of three iron chelators based on the desferrithiocin (DFT) pharmacophore, (S)-4, 5-dihydro-2-(2-hydroxyphenyl)-4-thiazolecarboxylic acid (desmethyldesferrithiocin, DMDFT, 2); (S)-4,5-dihydro-2-(2, 4-dihydroxyphenyl)-4-thiazolecarboxylic acid [4-(S)-hydroxydesazaDMDFT, 3); and (R)-2-(2-hydroxyphenyl)-4-oxazolinecarboxylic acid, the oxazoline analog of desazaDMDFT, 4, is described."( Pharmacokinetics of orally administered desferrithiocin analogs in cebus apella primates.
Bergeron, RJ; Weimar, WR; Wiegand, J, 1999
)
0.81

Bioavailability

ExcerptReferenceRelevance
" Bioavailability after oral administration is a unique property of desferrithiocin, and would make it an attractive alternative to deferoxamine."( The effect of desferrithiocin, an oral iron chelator, on T-cell function.
Bierer, BE; Nathan, DG, 1990
)
0.88
" In view of the previously described oral bioavailability of DFT, the marked ability of DFT and its derivatives to chelate hepatic iron, and their inability to affect brain DA or 5-HT metabolism, such siderophores appear potentially useful clinical iron chelators."( Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
Crichton, RR; Dexter, DT; Florence, A; Jenner, P; Ward, RJ, 1999
)
0.69

Dosage Studied

ExcerptRelevanceReference
" When administered to rodents at a daily dosage of 384 mumol/kg over a period of 10 days, drug 1 demonstrated severe renal toxicity."( A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.
Bergeron, RJ; Creary, EA; Daniels, RD; King, W; Luchetta, G; Moerker, T; Peter, HH; Streiff, RR; Wiegand, J, 1993
)
0.53
" In contrast, using the same dosing regimen, DFO and L1 only produced a 16% and 18% reduction, respectively, in liver iron levels."( Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
Crichton, RR; Dexter, DT; Florence, A; Jenner, P; Ward, RJ, 1999
)
0.69
" Owing to these results, po dosing was not attempted."( Desferrithiocin analogue based hexacoordinate iron(III) chelators.
Bergeron, RJ; Huang, G; McManis, JS; Smith, RE; Weimar, WR; Wiegand, J, 2003
)
1.76
" Selected ligands also underwent multiple and delayed dosing regimens."( Desferrithiocin analogue uranium decorporation agents.
Bergeron, RJ; Singh, S; Wiegand, J, 2009
)
1.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (18.92)18.7374
1990's15 (40.54)18.2507
2000's9 (24.32)29.6817
2010's6 (16.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.46 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.63%)5.53%
Reviews4 (10.53%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (86.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]